Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions

The incidence of renal cell carcinoma (RCC) is rising and metastatic RCC carries a very poor prognosis. The treatment paradigm for metastatic RCC has shifted dramatically in the last decade with multi-targeted tyrosine kinase inhibitors (TKI) previously used as first-line treatment but its utility i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tung, Iris, Sahu, Arvind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435744/
https://www.ncbi.nlm.nih.gov/pubmed/34527581
http://dx.doi.org/10.3389/fonc.2021.707214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435744/
https://www.ncbi.nlm.nih.gov/pubmed/34527581
http://dx.doi.org/10.3389/fonc.2021.707214

Ejemplares similares